Mrgprx2 antagonist and use thereof
Novel MRGPRX2 antagonist compounds, represented by formula IA, address the lack of effective treatments for mast cell-related diseases by inhibiting mast cell activation and degranulation, offering therapeutic benefits for conditions like urticaria and rheumatoid arthritis.
AU2024393601A1Pending Publication Date: 2026-07-09HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC
Patent Information
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC
- Filing Date
- 2024-12-06
- Publication Date
- 2026-07-09
AI Technical Summary
Technical Problem
Current treatments lack effective MRGPRX2 antagonists to address mast cell-related diseases such as drug-induced pseudo-allergic reactions, rosacea, atopic dermatitis, allergic contact dermatitis, urticaria, pruritus, mastocytosis, interstitial cystitis, pain, and inflammatory conditions like rheumatoid arthritis and asthma.
Method used
Development of novel compounds represented by formula IA, which act as MRGPRX2 antagonists, inhibiting mast cell activation and degranulation, thereby reducing the release of inflammatory factors.
Benefits of technology
The compounds effectively inhibit mast cell degranulation and vascular permeability, providing potential therapeutic benefits for mast cell-related diseases.
✦ Generated by Eureka AI based on patent content.
Abstract
Provided in the present invention are a compound as shown in formula IA, a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug thereof. The compound has a good MRGPRX2 antagonistic effect.
Need to check novelty before this filing date? Find Prior Art